Christopher Finch

Christopher Finch has held various strategic roles in the biotech industry. At Oruka Therapeutics, Christopher is currently the VP of Corporate Development & Strategy, focusing on developing biologics for chronic skin diseases like psoriasis. Previously, at CRISPR Therapeutics, as the Head of Strategy, Christopher played a key role in using CRISPR/Cas9 technology to create gene-based medicines. Christopher's insightful contributions can be traced back to their time at McKinsey & Company as a Business Analyst. Christopher holds an MPhil in Plant Sciences from the University of Cambridge and a BA in Biochemistry & Biophysics from Amherst College.